| A phase II study of allogeneic GM-CSF–transfected pancreatic tumor vaccine (GVAX) with Ipilimumab as maintenance treatment for metastatic pancreatic cancer AA Wu, KM Bever, WJ Ho, EJ Fertig, N Niu, L Zheng, RM Parkinson, ... Clinical cancer research 26 (19), 5129-5139, 2020 | 91 | 2020 |
| Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects KY Li, JL Yuan, D Trafton, JX Wang, N Niu, CH Yuan, XB Liu, L Zheng Chronic diseases and translational medicine 6 (01), 6-17, 2020 | 66 | 2020 |
| Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses T Xia, K Li, N Niu, Y Shao, D Ding, DL Thomas, H Jing, K Fujiwara, H Hu, ... Journal of Hematology & Oncology 15 (1), 37, 2022 | 34 | 2022 |
| Dual stromal targeting sensitizes pancreatic adenocarcinoma for anti-programmed cell death protein 1 therapy AB Blair, J Wang, J Davelaar, A Baker, K Li, N Niu, J Wang, Y Shao, ... Gastroenterology 163 (5), 1267-1280. e7, 2022 | 31 | 2022 |
| CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma J Wang, MT Saung, K Li, J Fu, K Fujiwara, N Niu, S Muth, J Wang, Y Xu, ... Journal of Experimental Medicine 219 (5), e20211631, 2022 | 31 | 2022 |
| Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells A Osipov, AB Blair, J Liberto, J Wang, K Li, B Herbst, Y Xu, S Li, N Niu, ... Cancer biology & medicine 18 (1), 206, 2021 | 23 | 2021 |
| Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model P Li, N Rozich, J Wang, J Wang, Y Xu, B Herbst, R Yu, S Muth, N Niu, K Li, ... Cancer letters 539, 215722, 2022 | 17 | 2022 |
| Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells J Wang, J Gai, T Zhang, N Niu, H Qi, DL Thomas, K Li, T Xia, C Rodriguez, ... Science Advances 10 (6), eadk1827, 2024 | 6 | 2024 |
| CLDN18. 2 bite engages effector and regulatory T cells for antitumor immune response in preclinical models of pancreatic cancer Y Xu, J Fu, MK Henderson, F Lee, N Jurcak, A Henn, J Wahl, Y Shao, ... Gastroenterology 165 (5), 1219-1232, 2023 | 5 | 2023 |
| Direct identification of HLA class I and class II-restricted T cell epitopes in pancreatic cancer tissues by mass spectrometry K Fujiwara, Y Shao, N Niu, T Zhang, B Herbst, M Henderson, S Muth, ... Journal of Hematology & Oncology 15 (1), 154, 2022 | 5 | 2022 |
| Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration K Li, J Wang, B Espinoza, Y Xiong, N Niu, J Wang, N Jurcak, N Rozich, ... Cancer Research 84 (6_Supplement), 6736-6736, 2024 | | 2024 |
| Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration Authors K Li, J Wang, B Espinoza, Y Xiong, N Niu, J Wang, N Jurcak, N Rozich, ... | | 2023 |
| Dual stromal targeting sensitizes pancreatic adenocarcinoma for anti-PD-1 therapy: Dual stromal targeting in Pancreatic Cancer AB Blair, J Wang, J Davelaar, A Baker, K Li, N Niu, J Wang, Y Shao, ... Gastroenterology 163 (5), 1267, 2022 | | 2022 |
| Abstract LB099: Direct identification of MHC class I and class II epitopes for TCR-based T cell therapy for pancreatic cancer T Zhang, J Wang, Y Shao, P Li, N Niu, B Herbst, J Gai, J Fu, P Zhang, J Yu, ... Cancer Research 82 (12_Supplement), LB099-LB099, 2022 | | 2022 |
| P08. 02 CCR2/CCR5 dual-antagonist ‘licenses’ the radiation-induced effector T-cell infiltration in the anti-PD-1 antibody-treated pancreatic adenocarcinoma J Wang, MT Saung, K Fujiwara, N Niu, A Narang, J He, L Zheng Journal for ImmunoTherapy of Cancer 9 (Suppl 1), 2021 | | 2021 |
| P08. 01 Rationale of using the combination of anti-PD-1 antibody and anti-IL-8 antibody for the pancreatic cancer treatment P Li, N Rozich, J Wang, J Gai, Y Xu, B Herbst, R Yu, S Muth, N Niu, K Li, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 1), 2021 | | 2021 |
| Abstract PR-004: Systemic and intratumoral immune profiling in metastatic pancreatic cancer patients who received front-line FOLFIRINOX and were treated with combination … AA Wu, KM Bever, WJ Ho, EJ Fertig, N Niu, L Zheng, RM Parkinson, ... Cancer Research 80 (22_Supplement), PR-004-PR-004, 2020 | | 2020 |
| Systemic and intratumoral immune profiling in metastatic pancreatic cancer patients who received front-line FOLFIRINOX and were treated with combination immunotherapy with CTLA … AA Wu, KM Bever, WJ Ho, EJ Fertig, N Niu, L Zheng, RM Parkinson, ... CANCER RESEARCH 80 (22), 2020 | | 2020 |
